PT-141: The Approval Is Real, and It Excludes Most of the People Buying It

What it is, and the argument about melanotan II

PT-141, generic name bremelanotide, is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone, molecular formula C50H68N14O10, PubChem CID 9941379. It is an agonist at melanocortin receptors including MC3R and MC4R, expressed primarily in the central nervous system rather than in the genital tissue itself (PMID 12851303). The label goes further: it activates the subtypes nonselectively, in the potency order MC1R, MC4R, MC3R, MC5R, MC2R, and at therapeutic doses the binding that matters is at MC1R and MC4R. MC1R is the pigmentation receptor, which explains the strangest number in the safety section below.

The relationship to melanotan II is where the published sources genuinely disagree, and I am not going to tidy that up. Hadley and Dorr, in Peptides in 2006, call PT-141 an analogue of melanotan II (PMID 16412534); Alwaal, Al-Mannie and Carrier, in Drug Design, Development and Therapy in 2011, call it an active metabolite of melanotan-II (PMID 22087063). Both peer reviewed, both on PubMed, and the words are not interchangeable: a metabolite inherits a share of its parent's story and an analogue does not. Structurally the two differ by a C-terminal hydroxyl in place of an amide. Either way they are separate molecules with different receptor selectivity and side effect profiles, so melanotan II's harm reports do not carry across. The rhabdomyolysis case that circulates (PMID 23121206) is a melanotan II case, and seeing it on a PT-141 page tells you what kind of page you are on.

The approval, read closely

Bremelanotide was approved on 21 June 2019 as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. That is the entire indication. Pull the prescribing information on DailyMed and read section 1 to the end, because the Limitations of Use printed under it are the two most useful lines written about this compound anywhere: not indicated for treatment of HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance.

The regimen is 1.75 mg injected subcutaneously by autoinjector into the abdomen or thigh at least 45 minutes before anticipated sexual activity, one dose in 24 hours at most, with more than eight in a month not recommended, with a stopping rule that is rare enough to notice: discontinue after 8 weeks if the patient does not report an improvement. Contraindicated in uncontrolled hypertension or known cardiovascular disease. I found no European Medicines Agency authorisation under either name, so the American approval is the only one I can confirm.

What the RECONNECT trials measured

Two identical phase 3 trials, NCT02333071 and NCT02338960, randomized 1,267 premenopausal women to 1.75 mg subcutaneous bremelanotide as needed or to placebo for 24 weeks (PMID 31599840). Both co-primary endpoints were questionnaires, the desire domain of the Female Sexual Function Index and item 13 of the Female Sexual Distress Scale. Integrated, desire rose 0.35 points and the distress item fell 0.33 points against placebo, both statistically significant, which the label renders as a desire change of +0.5 to +0.6 on drug versus +0.2 on placebo. The number of satisfying sexual events, the endpoint a user would recognise as the point, did not differ significantly between the groups (PMID 35076581).

Then the extension: 52 weeks of open-label treatment for the women who finished the core phase, everyone on active drug and nobody on placebo. Of the 856 eligible patients who completed the core phase, 684 elected to participate and 272 completed it (PMID 31599847). Because the extension drew from both arms, roughly half of those enrolling were taking bremelanotide for the first time. Free drug, no dummy arm, and that is the completion figure.

Two re-analyses sit on top of that record. Spielmans, in 2021, read the published results against the registered protocol and found 72.72 percent of protocol-listed outcomes unreported, adverse-event-induced discontinuation far higher on drug at a number needed to harm of 6, and participants measurably preferring placebo (PMID 33678061). Spielmans and Ellefson followed in 2024, reporting that results for 8 of the 11 efficacy outcomes specified on ClinicalTrials.gov had never been published and that the effect sizes ran from nil to small (PMID 36809187).

What was measured in men

Every male endpoint in the published literature is a measurement of erection, the approved indication in women is a desire indication, and no study bridges them. The only published subcutaneous efficacy data in men is a 2004 study: healthy males received 0.3 to 10 mg, men with an inadequate response to sildenafil received placebo, 4 mg or 6 mg, and erectile response on RigiScan reached significance at both 4 and 6 mg (PMID 14999221). The rest is intranasal, where the erectile response in men was statistically significant only above 7 mg (PMID 14963471).

I could not find a randomized controlled trial of subcutaneous bremelanotide in men published after 2010, nor a published trial of any design that has given men the 1.75 mg subcutaneous dose the approved product uses. Palatin announced a Phase 2 open-label dose-escalation study with a PDE5 inhibitor in roughly 50 men on 20 June 2024, topline promised by the end of that year, and I found no registration for it and no results.

Where the male convention comes from

Vendor, clinic and protocol pages converge on 1.0 to 2.0 mg subcutaneously for men, most often narrowed to 1.5 to 1.75 mg, injected 30 to 60 minutes before sexual activity, sometimes after a 0.5 to 1.0 mg test dose. Reported here as convention, not as evidence and not as instruction.

The unusual part is that it is traceable. Almost every other compound here has a community number that turns out to be a body-surface-area scaling off a rodent study. This one is the FDA-approved dose for premenopausal women, itself the top of a phase 2b trial that compared 0.75, 1.25 and 1.75 mg subcutaneously in 327 premenopausal women (PMID 27181790), lifted off the label and applied to men, the population that label excludes by name. No male dose-finding study supports it. The published male subcutaneous efficacy doses were 4 mg and 6 mg, so the convention runs at roughly a third to a half of the only subcutaneous dose ever shown to do anything in men.

The side effects are not subtle

In the phase 3 trials nausea occurred in 40.0 percent of bremelanotide-treated women against 1.3 percent on placebo, flushing in 20.3 against 0.3 percent, injection site reactions in 13.2 against 8.4 percent, headache in 11.3 against 1.9 percent. Four women in ten being sick is not a footnote, and nausea was the most common reason for discontinuation across the pooled safety review of 3,500 subjects in 43 completed studies, no deaths (PMID 35147466).

Now the pigmentation, and this is MC1R coming back. Focal hyperpigmentation occurred in about 1 percent of patients dosed up to eight times a month, and in 38 percent of patients given the drug daily for 8 days. It was more likely in patients with dark skin, and the label states that resolution was not confirmed in all patients. What drives that jump is how often you dose rather than how much, which is exactly the variable off-label use changes.

Behind the contraindication sit transient maximal increases of 6 mmHg systolic and 3 mmHg diastolic blood pressure and a heart rate reduction of up to 5 beats per minute, usually back to baseline within 12 hours. Bremelanotide is not named on the 2026 WADA Prohibited List.

My read

This is the rare entry where the evidence is not my complaint. Two phase 3 trials, 1,267 women, a regulator that read the file and approved the drug, and published re-analyses from people who think that was a mistake. Against most of what is in this reference, that is riches.

What a buyer should sit with is how small the thing bought turns out to be. Zero point three five of a point on a desire questionnaire. No significant difference in the number of satisfying sexual events. Two hundred and seventy-two women out of six hundred and eighty-four finishing a year of free drug.

That is the population where it is approved. Men are buying a number set in women, at roughly a third to a half of the only subcutaneous dose with a published male result behind it, for an effect on desire I could not find measured in a man. The compound is real and the approval is real. The join between those two facts and the person holding the vial is the part nobody checks.

If you have bought PT-141, was the Vyleesi approval mentioned at the point of sale, and did the words premenopausal women appear anywhere near it?

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.